BIOCHINA and Life Science Nation Team Up to Advance China–Global Biotech Partnerships

Collaboration connects Chinese innovation with international licensing partners at RESI JPM and BIOCHINA 2027

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

BOSTON and SUZHOU, China — Chinese biotech is changing the global partnering landscape. Life Science Nation (LSN) and Enmore BIO, organizer of BIOCHINA, are teaming up in 2027 to connect the companies driving that change with international licensing partners seeking their next opportunity.

The collaboration launches during J.P. Morgan Healthcare Week at RESI JPM, January 11–12 at the San Francisco Marriott Marquis, and continues at BIOCHINA, March 10–12 in Suzhou. Through reciprocal programs and coordinated outreach, the organizations will bring their communities together across two major life science gatherings. At RESI JPM, BIOCHINA will lead a one-hour China-focused session exploring how AI, innovation capabilities, and evolving partnership models are shaping the next generation of Chinese biotech. The discussion will bring Chinese industry leaders into direct conversation with RESI’s global licensing and partnering community about emerging technologies, business opportunities, and international collaboration.

At BIOCHINA, LSN will lead a reciprocal one-hour session on how international partners evaluate emerging companies, assess the team behind the science, and build productive relationships with founders. Final session titles and speakers will be announced separately.

“Both communities are looking across borders for their next opportunity,” said Dennis Ford, Founder and CEO of Life Science Nation. “Chinese companies are developing assets that global pharma is evaluating for future pipelines. International companies are seeking scientific relationships, development capabilities, and partners in China. Our job is to bring the right people together and help those conversations turn into business.”

The collaboration gives both organizations a platform to build a two-way innovation bridge—helping Chinese companies reach international markets while opening connections into China for global companies and strategic partners. Joint promotion through newsletters, industry networks and digital channels will extend the programs’ reach and introduce participants to opportunities across both communities.

The relationship has a proven starting point: LSN and Enmore Healthcare co-organized the first RESI Shanghai on November 12, 2019. Their 2027 collaboration brings those networks together again to advance the next generation of international partnerships.

About Life Science Nation

Life Science Nation connects emerging companies across drugs, devices, diagnostics and digital health with global investors and licensing partners through its databases, education, investability assessments, campaign services and RESI conference series.

About BIOCHINA

Founded in 2016, BIOCHINA has grown into the Asia-Pacific’s leading biotech industry event, with over 33,000 registered attendees by 2026. Centered on evolving industry needs, BIOCHINA integrates Exhibition, Conference, Partnering, and Events to: Connect supply and demand across the value chain, Share the latest technological trends, Drive project collaborations and funding, Promote global biotech cooperation. Moving forward, BIOCHINA remains committed to connect Innovators & enable Bio-industry.

RESI: https://www.resiconference.com/
BIOCHINA: https://www.biocn.cn/

The Business of Biotech Joins Next Phase

By Caitlin Dolegowski, Program Director, LSN

Building a biotech company requires far more than breakthrough science. It demands navigating complex organizational, funding, regulatory, and manufacturing realities. Starting with this issue, Life Science Nation (LSN) is bringing The Business of Biotech podcast directly into Next Phase, giving our community regular, in-inbox access to peer-driven executive insights on advancing novel therapies from early concepts to clinical success.

About The Business of Biotech

Created exclusively for the leaders of new and emerging biotech and pharmaceutical companies, The Business of Biotech tackles funding, R&D and organizational strategy, regulatory policy, manufacturing, and commercial considerations with insight from company founders, investors, and industry experts with lived experience translating novel science into new medicines.

Meet the Host: Ben Comer

The podcast is hosted by Ben Comer, Chief Editor of Life Science Leader magazine and Host of The Business of Biotech. Ben has covered the biopharmaceutical, medtech, and medical device industries for 15 years as a reporter and editor, and previously worked as a senior manager in PwC’s Health Research Institute. His deep industry background brings sharp, operational focus to every founder conversation.

What to Expect in Next Phase

Across Therapeutics, Medical Devices, Diagnostics, and Digital Health, LSN’s mission is to connect early-stage innovators with the global capital and licensing partners that move technologies forward. Embedding The Business of Biotech into Next Phase adds an executive storytelling dimension to our weekly newsletter, allowing readers to learn directly from founders actively building today’s biopharma companies.

Listen to this week’s featured episode below.

On this week’s episode of the Business of Biotech, Paul Peter Tak, M.D., Ph.D., CEO at Candel Therapeutics, talks about the path from Phase 3 data to BLA submission for aglatimagene in localized prostate cancer and why “in situ immunization” could change how solid tumors are treated. He also talks through leadership and operating choices for minimizing risk in late-stage development, how FDA’s Fast Track and RMAT designations aided communication and CMC planning, and how an outsourced commercial model can help companies prepare for launch and avoid premature fixed costs.

RESI JPM 2027 Partnering Platform Launches Monday, November 16

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wp

J.P. Morgan Healthcare Week is packed with satellite networking events, receptions, and pitch sessions competing for attention across San Francisco. Yet for early-stage life science startups, navigating the crowded hotel lobbies often results in fragmented conversations and low conversion rates.

When it comes to securing qualified capital and licensing discussions, RESI Partnering is the single most critical partnering platform of JPM Week.

Unlike general industry gatherings where early-stage founders are mixed in with late-stage and commercial companies, the RESI Partnering System is engineered specifically for Seed, Series A, and Series B innovators. With the platform officially going live on Monday, November 16, 2026, participants gain an immediate head start to connect directly with active decision-makers.

Why RESI Partnering Is the Most Critical Platform for Startups

The RESI system eliminates the guesswork of JPM Week by pairing deep matchmaking criteria with active capital allocators:

  • Targeted Investor Mandates: Filter investors not by generic categories, but by detailed investment criteria: indication, phase of development, modality, and capital structure preferences across Therapeutics, Medical Devices, Diagnostics, and Digital Health.
  • Verified, Active Checkbooks: Connect with over 700 active early-stage investors, venture funds, family offices, and corporate venture capital (CVC) scouts attending with explicit deployment mandates.
  • A Dedicated 5-Day Hybrid Structure: Lock in face-to-face meetings during the two in-person days in San Francisco (January 11 and 12), and continue building relationships through three dedicated virtual partnering days (January 13, 18, and 19) designed to fit around busy JPM schedules.
  • Two Full Months of Momentum: Early access starting November 16 ensures you can initiate dialogue, review incoming requests, and lock in your schedule long before arriving in San Francisco.

Free Live Webinar: RESI JPM Partnering Tutorial

To help attendees make the most of the software and maximize meeting acceptance rates, Life Science Nation is hosting a live, practical walkthrough on launch day:

  • Webinar: RESI JPM Partnering Tutorial
  • Date & Time: Monday, November 16, 2026 | 11:00 AM – 12:00 PM Eastern Time (US & Canada)
  • Registration: Sign Up for the Free Zoom Webinar

The LSN team will guide participants through advanced search filtering, best practices for writing high-converting meeting requests, follow-up strategies, and schedule management across both in-person and virtual sessions.

Learn how to craft compelling outreach messages and strategic follow-ups that drive engagement, secure high-priority meetings, and build lasting connections with potential partners and capital allocators: Watch LSN Event Partnering Process here.

Choosing Your Outreach Tier: Standard vs. Premier vs. Premier PLUS

Fundraising executives can align their partnering capabilities with their internal resources using three distinct tiers:

Features Standard
Base
Premier
+$750
PLUS
+$2,500
1-on-1 Partnering Access ✓ ✓ ✓
Investor Mandates & Profiles ✓ ✓ ✓
Direct Contact Info (Email/Phone) ✕ ✓ ✓
Granular Subsectors & Team Reqs ✕ ✓ ✓
Turnkey Outreach by LSN Team* ✕ ✕ ✓
*Limited Spots: Dedicated capacity is capped; Premier PLUS closes Nov 16.

Critical Milestone: Premier PLUS Closes on Launch Day (Nov 16)

Because Premier PLUS provides dedicated, hands-on campaign execution directly from LSN analysts, team capacity is strictly limited.

Registration for Premier PLUS will close on Monday, November 16, 2026.

  • New Registrants: Select Standard Partnering, add the Premier Package (+$750), or secure Premier PLUS (+$2,500) during checkout in the RESI JPM Registration Portal.
  • Already Registered for RESI JPM? Existing pass holders can add the Premier Package or claim one of the remaining Premier PLUS spots before November 16 by contacting the team directly at salescore@lifesciencenation.com.

Explore confirmed attending investors and event details at resiconference.com.

Register for RESI JPM & Add Premier Partnering

Help Shape Group Hotel Rates for Biotech Week Boston & RESI 2027: Take the 30-Second Lodging Survey

By Caitlin Dolegowski, Program Director, LSN

As the life science calendar ramps up, planning is already actively underway for next year’s Biotech Week Boston and the concurrent RESI Boston partnering conference.

Every autumn, thousands of early-stage biopharma and medtech founders, active investors, corporate pharmaceutical business development executives, and service providers descend upon Massachusetts. While the week delivers immense value through high-stakes dealmaking, one persistent hurdle facing attendees year after year is Boston’s notoriously tight lodging market.

To help our community manage travel overhead and secure prime accommodations, the Life Science Nation (LSN) and RESI conference operations team is currently actively negotiating discounted room blocks with premier 4-star properties across the Back Bay and Copley area – right in the central corridor of the week’s key activities.

To ensure we secure the deepest volume discounts and reserve the appropriate room inventory for your team, we need your direct input.

Why Lodging in Boston Requires Advance Coordination

Hotel pricing across central Boston spikes significantly during Biotech Week, driven by global industry demand. Individual reservations made late in the cycle often face exorbitant rack rates or require staying far outside the primary event clusters.

By consolidating the collective purchasing power of our attending founders, investors, and regional tech hub delegations, LSN negotiates dedicated group blocks designed to:

  • Cap Peak-Rate Volatility: Lock in pre-negotiated, below-market room rates during one of the city’s highest-occupancy weeks.
  • Keep Teams Centrally Located: Anchor attendees within walking distance of The Westin Copley Place and key partnering venues, eliminating unnecessary commute friction across town.
  • Guarantee Sufficient Inventory: Provide your executive team, board members, and business development leads with confirmed space before room blocks sell out.

Take the 30-Second Lodging Survey

Our room block allocations and target rate negotiations directly depend on the aggregate requirements of the companies planning to participate.

Whether your organization plans to send a single executive or an entire delegation, please take 30 seconds to share your general lodging preferences:

Take the 30-Second Biotech Week Boston Hotel Survey

(The survey is completely anonymous, requires no login, and takes under a minute to complete.)

What Happens Next

Your feedback on target price points, stay duration, and room count will directly equip our negotiation team as we finalize contracts with Back Bay hotel partners in the coming weeks. Once group blocks are locked in, confirmed booking links and preferential access will be shared with registered delegates and newsletter subscribers.

Thank you for helping us make Biotech Week Boston both highly productive and cost-effective for the early-stage life science community.

For any specific questions regarding group delegations, corporate sponsorships, or partnering registration, please reach out to the RESI team at resi@lifesciencenation.com.

Take the 30-Second Biotech Week Boston Hotel Survey

Investor Outreach Support at RESI JPM 2027

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

RESI JPM 2027 will take place January 11 and 12 at the San Francisco Marriott Marquis, with virtual partnering days on January 13, 18 and 19.

For early-stage life science companies, effective partnering starts with finding investors whose interests and requirements align with their company. RESI verifies and interviews investor attendees, then creates curated profiles for the partnering platform. With a standard RESI registration, companies can search investor profiles by investor type, name, indications, phase of development, capital structure preference and investment stage preference.

Companies seeking more detail can choose the Premier Package or Premier PLUS. Each option adds support for a different stage of the outreach process.

Premier Package

The Premier Package costs $750 and gives companies additional investor information to guide self-managed outreach. In addition to the details available through standard RESI access, Premier profiles include direct investor contact information, sectors and subsectors of interest, and company and management team requirements.

This added information can help fundraising teams identify investors that better match their company and contact them directly.

Premier PLUS

Premier PLUS costs $2,500 and includes all Premier Package benefits, along with hands-on outreach support from the Life Science Nation team.

LSN helps identify relevant investors and strategic partners, prepares tailored messaging, manages communications and scheduling, and works to secure confirmed meetings before the conference. Premier PLUS is designed for companies that want support coordinating the outreach process while they focus on their fundraising campaign. Availability for Premier PLUS is limited.

Option 1: Premier Package
$750
Full Contact & Mandate Intelligence
Unlock direct investor contact details and detailed investment criteria to execute precise self-managed outreach:
• Direct Contact Info: Verified emails and direct phone numbers for decision makers.
• Granular Criteria: Sectors and subsectors of interest.
• Mandate Fit: Company & management team requirements.
• Complete investor profiles and preferences.
Option 2: Premier PLUS
$2,500
Full Turnkey Outreach Management
Hands-on support from the LSN team to run your investor partnering from start to finish:
• Target Identification: Sourcing relevant investors and strategic partners.
• Custom Messaging: Tailored, professional pitch copy for each contact.
• Active Management: Full communication and schedule coordination.
• Meeting Delivery: Confirmed meetings booked prior to arrival.

*Limited Spots: Dedicated 1-on-1 team capacity is strictly capped.
⏰ Deadline: Premier PLUS registration closes Monday, November 16!
(Includes all Premier Package benefits)

📊 Feature Comparison: RESI Standard vs. Premier Package

Features RESI Standard Premier Package
Investor Type ✓ ✓
Investor Name ✓ ✓
Indications ✓ ✓
Phase of Development ✓ ✓
Capital Structure Preference ✓ ✓
Investment Stage Preference ✓ ✓
Direct Investor Contact Info (Email, Phone) ✕ ✓
Sectors & Subsectors of Interest ✕ ✓
Company & Management Team Requirements ✕ ✓

Choosing the right option

Standard RESI access provides investor profiles with core information for searching and evaluating potential matches. The Premier Package adds contact details and more specific investment criteria for companies managing their own outreach. Premier PLUS adds LSN support for research, messaging, communication and meeting coordination.

How to add a Premier option

Companies registering for RESI JPM 2027 can select Premier or Premier PLUS as an add-on in the registration portal. Companies that have already registered can contact salescore@lifesciencenation.com to add an upgrade to their existing account.

Register for RESI JPM & Add Premier Partnering

The Problem Isn’t Access to Capital. It’s Being Investable. Why early-stage life science companies need a commercialization engine, not another introduction

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

For years, LSN ran an investment banking program for early-stage life science companies. It taught us something important: capital-raising solutions work best when a transaction is imminent. For most early-stage companies, it isn’t. Seed, Series A, and Series B companies are still working through the scientific, clinical, regulatory, commercial, and financing risks that determine whether investors will engage. They pitch technology and market potential. Investors ask what’s been proven, which risks have been retired, and what evidence is still missing. More introductions won’t close that gap. These companies need more than deal preparation. They need a commercialization process that can run for months or years.

The Commercialization Engine
LSN is building one with global partners: universities, research institutes, regional clusters, and innovation programs with technology-rich ecosystems. Our partners advance discoveries, generate evidence, and retire development risks. LSN provides assessment intelligence, investability preparation, and access to the global capital and licensing marketplace. LSN’s agentic AI engines support this process. They help evaluate companies through the eyes of investors and licensing partners, an approach already used with more than 250 clients. They also identify and rank relevant global capital and licensing targets.

Stage Commercialization Capability
Scientific assessment and de-risking Scientific and commercialization partners
Investability preparation LSN Investability Assessment, LSN Labs, de-risked decks
Partner identification LSN Matching Engine and Global Target Lists
Campaign execution BD Assist
Global partnering RESI Conference Series

Companies enter wherever their readiness puts them. Agentic AI tools are becoming widely available. LSN’s advantage is the global network, relationships, proprietary databases, and market intelligence built through years of direct work with investors, licensing partners, and companies. That depth of intelligence goes well beyond the cursory matches available from web searches.

BD Assist: Where Preparation Becomes Execution
A seasoned CEO may know a few dozen investors and can find a few hundred more. That still isn’t enough. LSN’s Matching Engine generates a Global Target List of 800–1,000 prospective capital and licensing partners. BD Assist puts that intelligence to work through sustained outreach, engagement tracking, and follow-up over the 9–18 months that early-stage campaigns can require. The CEO leads investor relationships, negotiations, and transactions. LSN manages targeting intelligence, sets up the meetings, and provides campaign support. The cost is $5,000 a month, with no success fee. LSN leverages databases that capture current and forward-looking mandates and historical VC and Pharma transactions, then integrates into all of LSN’s RESI events to add face-to-face or virtual meetings with investors and licensing partners worldwide.

Who Is the Perfect Fit for BD Assist?
The ideal client is an experienced life science CEO who knows how to raise capital and has an investable asset and a credible development plan. What they lack is the global reach and campaign infrastructure to pursue hundreds of prospective investors and licensing partners. This CEO doesn’t need someone to explain fundraising or negotiate a term sheet. They need a dedicated team to identify the right global targets, run a disciplined campaign, and keep opportunities moving while they run their company. BD Assist is not for every company that needs money. Companies still working through fundamental scientific or investability issues may first need assessment, de-risking, and preparation.

The CEO knows how to raise the money. LSN provides the global intelligence and reach, including meeting setup and campaign infrastructure, to help them find it.

To see whether BD Assist is the right fit for your company, contact the LSN team. LSN BD will provide a free investability assessment report, show you what your global target list should look like, and offer commentary on your messaging for your target audience.

Get Your LSN Labs Company Assessment Report

Watch the Asset Flow, Not the Equity Flow: What I Learned at BioJapan

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

I recently returned from BioJapan, and the one takeaway I want to share with my global network is this: stop viewing Asia Pacific as a single market.

Regulations on both sides of the Pacific have made equity deals between the US and China much harder. But capital hasn’t stopped moving. It has changed form. Where equity deals run into friction, pharma licenses the asset instead. Chinese biotechs out-licensed $60 billion of assets in the first quarter of this year alone, up 73% from the same period a year earlier. That includes AstraZeneca’s deal with CSPC worth up to $18.5 billion. Large pharma faces a steep patent cliff before 2030, so its appetite for clinical-stage assets isn’t going away.

So watch the asset flow, not the equity flow. Here is what actually changed for me in Japan. I went in thinking about APAC as one market with local variations. It isn’t. It is three markets with three completely different jobs, and once you see them separately, the whole region stops looking confusing.

Three Markets, Not One

Each market plays a different role. China produces more assets than its domestic capital can absorb. Australia and Southeast Asia have the clinical infrastructure others can use. Japan and Korea stand out because they have both: a growing supply of academic innovation and deep corporate balance sheets looking for it.

Region Sell Side
(Early-Stage Assets)
Buy Side
(VC / PE / Pharma)
Characterization
Mainland China A large volume of high-quality assets, many moving faster than domestic capital can fund them Domestic equity is selective and US venture investment has pulled back, while global pharma licensing runs at record levels “The Asset Reservoir”
Japan, South Korea, & Taiwan A deep, largely untapped pool of academic assets, alongside mature platforms: ADCs and regenerative medicine in Japan, AI-driven discovery and diagnostics in Korea. Taiwan continues to produce world-class assets Active corporate venture arms and well-capitalized conglomerates “The Strategic Capital Track”
Australia & Southeast Asia Excellent trial infrastructure producing fast, high-quality human data Cross-border investors using local efficiency as a launchpad for global programs “The Clinical Fast Track”

Japan: Where Assets Meet Capital

Universities such as the University of Tokyo, Kyoto University, Keio University, Osaka University, Kobe University, and the University of Tsukuba, with RIKEN anchoring the discovery end, are producing a remarkable range of new assets across drugs, devices, diagnostics, and digital health. What’s new is a coordinated government effort to carry those assets to market:

  • AMED runs a 2:1 double match-up program. When a registered VC invests in a Japanese drug discovery startup, AMED can add up to twice that amount in non-dilutive funding, awarded per pipeline rather than per company, so a startup with three approved programs can draw on it three times.
  • MEDISO, under the Ministry of Health, Labor and Welfare, pairs ventures and university spinouts with experts in regulatory affairs, international development, and fundraising.
  • J-Bridge, run by JETRO, connects international innovators with Japanese corporates.

Three state-backed institutions, answering to different ministries, are working on the same bottleneck, and regional clusters are carrying that work into the field. For global investors and partners, that means Japanese assets now arrive better funded and better prepared, and Japanese corporate capital is easier to reach than it has been in years.

One Japanese advantage almost nobody prices correctly: Japan maintains a conditional, time-limited approval pathway for regenerative medicine products that can grant market access on evidence of probable benefit. No other major market offers that. If you have a cell or gene therapy and have never looked at Japan as a first market rather than a third one, you are leaving an option unexercised.

KBIC, the Kobe Biomedical Innovation Cluster, and LSN are working together to strengthen the commercialization pathway for Japanese life science companies through entrepreneur education, company preparation, capital formation, and international business development. At BioJapan in October, LSN presented joint sessions with KBIC, including one alongside MEDISO, on startup readiness and global fundraising.

RESI Asia: Tokyo and Kobe

That is why RESI is coming to Japan. RESI Asia Japan convenes in Tokyo on April 13, 2027, for global partnering. We expect to announce more events around RESI before and after the 13th

The Bottom Line

Regulatory boundaries have changed the rules, but pharma’s appetite for licensing shows the underlying science has never been more valuable. Watch the asset flow, not the equity flow. I look forward to seeing many of you in Tokyo next April.

RESI Asia Japan Registration:

Japan-base Registration (JPY)
Non-Japan-base Registration (USD)